923289-59-2

Basic information

• Product Name: 4-Isopropylthiazole-2-carbonyl chloride
• Synonyms: 4-Isopropylthiazole-2-carbonyl chloride;4-(propan-2-yl)-1,3-thiazole-2-carbonyl chloride;MILXVFASHGWQQV-UHFFFAOYSA-N
• CAS NO: 923289-59-2
• Molecular Formula: C₇H₈ClNOS
• Molecular Weight: 189.66252
• Mol File: 923289-59-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Isopropylthiazole-2-carbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Isopropylthiazole-2-carbonyl chloride(923289-59-2)
• EPA Substance Registry System: 4-Isopropylthiazole-2-carbonyl chloride(923289-59-2)

Safety Data

• Hazardous Substances Data: 923289-59-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Isopropylthiazole-2-carbonyl chloride is used as a versatile building block for the preparation of various pharmaceuticals and agrochemicals. It serves as a key starting material for the synthesis of biologically active molecules and can be utilized in the development of new drugs and medicinal compounds.
Used in Organic Synthesis:
4-Isopropylthiazole-2-carbonyl chloride is used as a valuable intermediate in organic synthesis, enabling the creation of a wide range of thiazole-based compounds with potential applications in various fields.

Upstream product

• 300831-06-5 4-isopropylthiazole-2-carboxylic acid 
• 79-37-8 oxalyl dichloride 
• 1108658-73-6 4-isopropylthiazole-2-carboxylic acid 
• 19967-55-6 1-bromo-3-methyl-2-butanone 
• 156589-82-1 4-(1-methylethyl)thiazole-2-carboxylic acid ethyl ester 
• 563-80-4 3-methyl-butan-2-one 

Downstream Products

• 42465-53-2 1-(2-amino-4-methoxyphenyl)ethanone 
• 300831-07-6 N-(2-acetyl-5-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 
• 1108658-94-1 N-(6-acetyl-3-chloro-4-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 
• 923289-21-8 8-methyl-2-[4-(1-methylethyl)-1,3-thiazol-2-yl]-7-(methyloxy)-4-quinolinol 
• 923289-20-7 N-(6-acetyl-2-methyl-3-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 

Relevant articles and documents

2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof